TAK1 review_R1 final.pdf (2.4 MB)
TAK1 signaling is a potential therapeutic target for pathological angiogenesis
journal contribution
posted on 2023-05-20, 22:17 authored by Zhu, L, Lama, S, Tu, L, Dusting, GJ, Wang, J-H, Guei-Sheung LiuGuei-Sheung LiuAngiogenesis plays a critical role in both physiological responses and disease pathogenesis. Excessive angiogenesis can promote neoplastic diseases and retinopathies, while inadequate angiogenesis can lead to aberrant perfusion and impaired wound healing. Transforming growth factor β activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, is a key modulator involved in a range of cellular functions including the immune responses, cell survival and death. TAK1 is activated in response to various stimuli such as proinfammatory cytokines, hypoxia, and oxidative stress. Emerging evidence has recently suggested that TAK1 is intimately involved in angiogenesis and mediates pathogenic processes related to angiogenesis. Several detailed mechanisms by which TAK1 regulates pathological angiogenesis have been clarifed, and potential therapeutics targeting TAK1 have emerged. In this review, we summarize recent studies of TAK1 in angiogenesis and discuss the crosstalk between TAK1 and signaling pathways involved in pathological angiogenesis. We also discuss the approaches for selectively targeting TAK1 and highlight the rationales of therapeutic strategies based onTAK1 inhibition for the treatment of pathological angiogenesis.
Funding
National Health & Medical Research Council
History
Publication title
AngiogenesisISSN
0969-6970Department/School
Menzies Institute for Medical ResearchPublisher
Springer NetherlandsPlace of publication
NetherlandsRights statement
© The Author(s), under exclusive licence to Springer Nature B.V. 2021. Post-prints are subject to Springer Nature re-use termsRepository Status
- Restricted